MARKET

CYCN

CYCN

Cyclerion Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.500
-0.020
-0.57%
After Hours: 3.500 0 0.00% 16:47 01/28 EST
OPEN
3.540
PREV CLOSE
3.520
HIGH
3.600
LOW
3.390
VOLUME
270.00K
TURNOVER
--
52 WEEK HIGH
22.85
52 WEEK LOW
1.690
MARKET CAP
96.14M
P/E (TTM)
-0.7503
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of CYCN and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

CYCN News

  • DDD, NVTA among premarket gainers
  • Seeking Alpha - Article.01/13 14:27
  • Cyclerion announces IW-6463 phase 1 healthy volunteer study results that support further development for neurodegenerative diseases
  • GlobeNewswire.01/13 12:00
  • The Week Ahead In Biotech: JPMorgan Healthcare Conference, FDA Panel Reviews Opioid Pain Drugs, I-Mab's IPO
  • Benzinga.01/12 22:05
  • The Week Ahead In Biotech: JPMorgan Healthcare Conference, FDA Panel Reviews Opioid Pain Drugs, I-Mab's IPO
  • Benzinga.01/12 22:05

More

Industry

Biotechnology & Medical Research
+0.97%
Pharmaceuticals & Medical Research
+0.58%

Hot Stocks

Name
Price
%Change

About CYCN

Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing treatments for serious and orphan diseases. The Company develops guanylate cyclase (sGC) stimulators. The Company’s portfolio includes five sGC stimulator programs: olinciguat, praliciguat, IW-6463 and two organ-targeted programs. Olinciguat is an oral, once-daily vascular sGC stimulator for patients suffering from sickle cell disease. Olinciguat is in Phase II trial. Praliciguat is an oral, once-daily systemic sGC stimulator for heart failure with preserved ejection fraction (HFpEF) and for diabetic nephropathy. Praliciguat is in two separate Phase II trials. IW-6463 is a central nervous system-penetrant oral sGC stimulator. IW-6463 is in a Phase I and is designed to treat serious and orphan neurodegenerative diseases. Its two organ-targeted programs are designed to address serious and orphan diseases of the liver and lung.
More

Webull offers Cyclerion Therapeutics Inc (CYCN) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.